Actively Recruiting
Phase I Study of Revumenib as Maintenance Therapy After Stem Cell Transplant in Acute Leukemia with KMT2A or NPM1 Mutations
Led by City of Hope Medical Center · Updated on 2026-10-19
27
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating revumenib as a maintenance therapy for patients with acute leukemia who have undergone allogeneic hematopoietic cell transplantation alloHCT. This phase I trial aims to assess the safety, side effects, best dose, and effectiveness of revumenib, a menin inhibitor that blocks key gene activation driving leukemia cell growth. The study focuses on patients with specific genetic types of acute leukemia, including KMT2A rearranged or NPM1 mutated forms. Participants start revumenib treatment between 50 and 150 days after alloHCT. They receive the drug orally once daily or every 12 hours for 28-day cycles, repeating up to 2 years if there is no disease progression or unacceptable side effects. The study includes dose escalation and expansion phases. During screening and the trial, participants undergo bone marrow biopsies, echocardiograms as needed, and blood sample collections. Throughout the study, researchers monitor safety by tracking adverse events and assess molecular responses, survival rates, relapse, graft versus host disease, and immune cell recovery. Participants have regular evaluations including bone marrow aspirations and quality-of-life assessments. After completing treatment, follow-up visits occur at 30 days and then every 3 months for up to 2 years to monitor long-term outcomes.
CONDITIONS
Brief Title
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
Research Team
B
Brian Ball, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here